TIDES - Informa Connect

@TIDESInforma

The official twitter account for the Informa Connect TIDES portfolio. Your home for all things Oligonucleotide & Peptide Therapeutics. Next event:

Boston, MA
Vrijeme pridruživanja: svibanj 2009.

Tweetovi

Blokirali ste korisnika/cu @TIDESInforma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @TIDESInforma

  1. Prikvačeni tweet
    Poništi
  2. How can you avoid new therapies being derailed by regulatory processes? This whitepaper presents successful strategies for peptide, oligonucleotide and mRNA therapeutic products.

    Poništi
  3. 3. velj

    Edie Stringfellow identifies six best practices that biotech and pharma companies can use to directly improve their workplace culture.

    Poništi
  4. 3. velj

    How can you navigate the regulatory maze to get peptide, oligonucleotide and mRNA therapies to market? This whitepaper presents successful strategies & case studies.

    Poništi
  5. 2. velj

    Knud Jensen, Professor, Department of Chemistry at , discusses how can academia and biotechs can work better together to both benefit

    Poništi
  6. 2. velj

    Macarena Hernández Jiménez, CSO at AptaTargets, discusses how the company is using therapeutic aptamers to treat , as well as the main challenges that need to be overcome

    Poništi
  7. 1. velj

    What’s the recipe for getting peptide, oligonucleotide and mRNA treatments approved? This whitepaper explores how to navigate the current regulatory frameworks.

    Poništi
  8. 1. velj

    How are leading biotech and pharma organizations successfully implementing initiatives? Here are 6 best practices chosen by Edie Stringfellow

    Poništi
  9. 31. sij

    How can you avoid new therapies being derailed by regulatory processes? This whitepaper presents successful strategies for peptide, oligonucleotide and mRNA therapeutic products.

    Poništi
  10. 30. sij

    John Lopez, Process Development Chemist at , explores how can revolutionize chemistry to make it a driven field

    Poništi
  11. 29. sij

    How can you navigate the regulatory maze to get peptide, oligonucleotide and mRNA therapies to market? This whitepaper presents successful strategies & case studies.

    Poništi
  12. 29. sij

    Edie Stringfellow identifies six best practices that biotech and pharma companies can use to directly improve their workplace culture.

    Poništi
  13. 28. sij

    Knud Jensen, Professor, Department of Chemistry at , discusses how can academia and biotechs can work better together to both benefit

    Poništi
  14. 27. sij

    How are leading biotech and pharma organizations successfully implementing initiatives? Here are 6 best practices chosen by Edie Stringfellow

    Poništi
  15. 27. sij

    What’s the recipe for getting peptide, oligonucleotide and mRNA treatments approved? This whitepaper explores how to navigate the current regulatory frameworks.

    Poništi
  16. 26. sij

    Christine Dieterich, Senior Project Manager CMC & Preclinical at , explores how the company is working with single strain focused on inflammatory diseases

    Poništi
  17. 24. sij

    John Lopez, Process Development Chemist at , explores how can revolutionize chemistry to make it a driven field

    Poništi
  18. 24. sij

    Edie Stringfellow identifies six best practices that biotech and pharma companies can use to directly improve their workplace culture.

    Poništi
  19. 22. sij

    Knud Jensen, Professor, Department of Chemistry at , discusses how can academia and biotechs can work better together to both benefit

    Poništi
  20. 22. sij

    How are leading biotech and pharma organizations successfully implementing initiatives? Here are 6 best practices chosen by Edie Stringfellow

    Poništi
  21. 20. sij

    Macarena Hernández Jiménez, CSO at AptaTargets, discusses how the company is using therapeutic aptamers to treat , as well as the main challenges that need to be overcome

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·